JP3570516B2 - 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ） - Google Patents

増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ） Download PDF

Info

Publication number
JP3570516B2
JP3570516B2 JP50346495A JP50346495A JP3570516B2 JP 3570516 B2 JP3570516 B2 JP 3570516B2 JP 50346495 A JP50346495 A JP 50346495A JP 50346495 A JP50346495 A JP 50346495A JP 3570516 B2 JP3570516 B2 JP 3570516B2
Authority
JP
Japan
Prior art keywords
kgf
sequence
cell
expression
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50346495A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09500267A (ja
Inventor
ジェイ． ゴスポダロウィッツ，デニス
マシアーツ，フランク
Original Assignee
カイロン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カイロン コーポレイション filed Critical カイロン コーポレイション
Publication of JPH09500267A publication Critical patent/JPH09500267A/ja
Application granted granted Critical
Publication of JP3570516B2 publication Critical patent/JP3570516B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
JP50346495A 1993-06-29 1994-04-28 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ） Expired - Fee Related JP3570516B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8642793A 1993-06-29 1993-06-29
US08/086,427 1993-06-29
PCT/US1994/004694 WO1995001434A1 (en) 1993-06-29 1994-04-28 A truncated keratinocyte growth factor (kgf) having increased biological activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004034289A Division JP2004166709A (ja) 1993-06-29 2004-02-10 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）

Publications (2)

Publication Number Publication Date
JPH09500267A JPH09500267A (ja) 1997-01-14
JP3570516B2 true JP3570516B2 (ja) 2004-09-29

Family

ID=22198501

Family Applications (4)

Application Number Title Priority Date Filing Date
JP50346495A Expired - Fee Related JP3570516B2 (ja) 1993-06-29 1994-04-28 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）
JP2004034289A Withdrawn JP2004166709A (ja) 1993-06-29 2004-02-10 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）
JP2005333438A Withdrawn JP2006075173A (ja) 1993-06-29 2005-11-17 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）
JP2008301630A Expired - Lifetime JP4662569B2 (ja) 1993-06-29 2008-11-26 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2004034289A Withdrawn JP2004166709A (ja) 1993-06-29 2004-02-10 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）
JP2005333438A Withdrawn JP2006075173A (ja) 1993-06-29 2005-11-17 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）
JP2008301630A Expired - Lifetime JP4662569B2 (ja) 1993-06-29 2008-11-26 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）

Country Status (25)

Country Link
US (7) US5677278A (enExample)
EP (2) EP1493812A3 (enExample)
JP (4) JP3570516B2 (enExample)
KR (1) KR960703433A (enExample)
CN (1) CN1129955A (enExample)
AT (1) ATE278777T1 (enExample)
AU (1) AU681405B2 (enExample)
BG (1) BG100236A (enExample)
BR (1) BR9407035A (enExample)
CA (1) CA2166278A1 (enExample)
CZ (1) CZ343795A3 (enExample)
DE (2) DE122006000005I2 (enExample)
DK (1) DK0706563T3 (enExample)
ES (1) ES2227527T3 (enExample)
FI (1) FI956203A7 (enExample)
FR (1) FR06C0004I2 (enExample)
HU (1) HUT73453A (enExample)
LU (1) LU91215I2 (enExample)
NL (1) NL300217I2 (enExample)
NO (1) NO955189D0 (enExample)
NZ (1) NZ266622A (enExample)
PL (1) PL312257A1 (enExample)
PT (1) PT706563E (enExample)
SK (1) SK153295A3 (enExample)
WO (1) WO1995001434A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0555205T3 (da) * 1989-01-31 2001-03-05 Jeffrey S Rubin DNA, der koder for en væstfaktor, som er specifik for epitelceller
US7026291B1 (en) 1989-01-31 2006-04-11 The United States Of America As Represented By The Department Of Health And Human Services Epithelial cell specific growth factor, keratinocyte growth factor (KGF)
US5814605A (en) * 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
NZ266622A (en) * 1993-06-29 1997-10-24 Chiron Corp Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
US7084119B2 (en) * 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
EP0804479B1 (en) * 1994-10-13 2006-10-11 Amgen Inc., Method of treating diabetes mellitus using kgf
AU745815B2 (en) * 1994-10-13 2002-04-11 Biovitrum Ab (Publ) Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
DK0785949T3 (da) * 1994-10-13 2003-08-18 Amgen Inc Fremgangsmåde til oprensning af keratinocytvækstfaktorer
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
AU7248896A (en) * 1995-10-11 1997-04-30 Chiron Corporation Combination pdgf, kgf, igf and igfbp for wound healing
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
DE69728415T2 (de) * 1996-10-15 2004-08-12 Amgen Inc., Thousand Oaks Produkte des keratinocyten-wachstumsfaktors 2 (kgf-2)
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
SI0935652T1 (en) * 1996-10-15 2004-06-30 Amgen Inc. Keratinocyte growth factor-2 products
CA2294569A1 (en) * 1997-06-19 1998-12-23 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US20080233086A1 (en) * 1997-09-05 2008-09-25 Canbiocin Inc. Expression Vectors for Treating Bacterial Infections
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
EP1041996A4 (en) * 1997-12-22 2003-05-14 Human Genome Sciences Inc KERATINOCYTE GROWTH FACTOR-2 FORMULATIONS
CN1295579A (zh) * 1998-02-13 2001-05-16 人类基因组科学公司 角质细胞生长因子2的治疗应用
DE19934510B4 (de) * 1999-07-22 2009-04-16 Vermicon Ag Verfahren zum Nachweis von Mikroorganismen
WO2001027301A2 (en) 1999-10-15 2001-04-19 The Rockefeller University System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
DE10024334B4 (de) * 2000-05-17 2006-06-01 Medigene Ag Verfahren zum Einbringen von Nukleinsäure in eine Zelle (Transfektion) mittels Calciumphosphat
AU2002236477A1 (en) 2000-11-21 2002-06-03 The Texas A & M University System Fgf-affinity chromatography
EP1357931A2 (en) * 2001-01-08 2003-11-05 Human Genome Sciences, Inc. Keratinocyte growth factor-2
JP4279554B2 (ja) 2001-02-19 2009-06-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法
MXPA04001526A (es) 2001-08-21 2004-05-31 Chiron Corp Composiciones de polipetidos kgf.
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
MX2007006822A (es) * 2004-12-15 2007-07-24 Amgen Inc Formulaciones terapeuticas para el factor de crecimiento de queratinocitos.
US20060183712A1 (en) * 2005-02-17 2006-08-17 The Texas A&M University System Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
WO2007081447A2 (en) * 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
KR20240053580A (ko) 2021-08-30 2024-04-24 유니켐 레버러토리스 리미티드 염증성 질환의 치료용 단백질 조성물
KR102691028B1 (ko) * 2021-11-15 2024-08-05 (주)피앤피바이오팜 안정성이 증가된 인간 각질세포 성장인자1 변이체 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0555205T3 (da) 1989-01-31 2001-03-05 Jeffrey S Rubin DNA, der koder for en væstfaktor, som er specifik for epitelceller
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5814605A (en) 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
NZ266622A (en) * 1993-06-29 1997-10-24 Chiron Corp Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
SI0785950T1 (en) 1994-10-13 2003-08-31 Amgen Inc. Keratinocyte growth factor analogs
EP0804479B1 (en) 1994-10-13 2006-10-11 Amgen Inc., Method of treating diabetes mellitus using kgf

Also Published As

Publication number Publication date
ES2227527T3 (es) 2005-04-01
JP2009062396A (ja) 2009-03-26
NO955189L (no) 1995-12-20
ATE278777T1 (de) 2004-10-15
NZ266622A (en) 1997-10-24
CZ343795A3 (en) 1996-07-17
US6677301B1 (en) 2004-01-13
US5677278A (en) 1997-10-14
KR960703433A (ko) 1996-08-17
NL300217I1 (nl) 2006-04-03
JP2006075173A (ja) 2006-03-23
JP4662569B2 (ja) 2011-03-30
AU6820894A (en) 1995-01-24
SK153295A3 (en) 1996-11-06
CA2166278A1 (en) 1995-01-12
DE122006000005I1 (de) 2006-08-10
US5863767A (en) 1999-01-26
EP0706563A1 (en) 1996-04-17
EP1493812A2 (en) 2005-01-05
DK0706563T3 (da) 2005-01-31
JP2004166709A (ja) 2004-06-17
US5843883A (en) 1998-12-01
CN1129955A (zh) 1996-08-28
JPH09500267A (ja) 1997-01-14
HUT73453A (en) 1996-08-28
BR9407035A (pt) 1996-03-12
FR06C0004I1 (enExample) 2006-03-10
EP1493812A3 (en) 2006-02-08
AU681405B2 (en) 1997-08-28
NL300217I2 (nl) 2006-05-01
FI956203A0 (fi) 1995-12-22
WO1995001434A1 (en) 1995-01-12
PL312257A1 (en) 1996-04-01
LU91215I2 (en) 2006-03-27
US20090093400A1 (en) 2009-04-09
NO955189D0 (no) 1995-12-20
BG100236A (en) 1996-07-31
PT706563E (pt) 2005-01-31
HU9503857D0 (en) 1996-02-28
EP0706563B1 (en) 2004-10-06
US6074848A (en) 2000-06-13
DE69434053D1 (de) 2005-01-20
DE69434053T2 (de) 2006-02-23
DE122006000005I2 (de) 2006-11-23
FI956203A7 (fi) 1996-02-07
FR06C0004I2 (fr) 2006-12-29
US5773586A (en) 1998-06-30

Similar Documents

Publication Publication Date Title
JP4662569B2 (ja) 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子（ｋｇｆ）
JP6621752B2 (ja) 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
US7361738B2 (en) Megakaryocyte stimulating factors
US9925243B2 (en) Chimeric fibroblast growth factor (FGF) 2/FGF1 peptides and methods of use
US20170291931A1 (en) Fgf2 truncations and mutants and uses thereof
JPH10500300A (ja) 単球走化性蛋白質−４
CA2201762C (en) Method for purifying keratinocyte growth factors
US20180319857A1 (en) Fgf2 truncations and mutants and uses thereof
US6008328A (en) Method for purifying keratinocyte growth factors
US7247452B2 (en) Truncated keratinocyte growth factor (KGF) having increased biological activity
CA2210471A1 (en) Human chemokine beta-11 and human chemokine alpha-1
HK1066827A (en) Megakaryocyte stimulating factors

Legal Events

Date Code Title Description
A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20031110

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040608

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040616

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees